Temozolomid-Teva 180 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid-teva 180 mg capsule

teva pharma ag - temozolomidum, ammonii hydroxidum - capsule - temozolomidum 180 mg, lactosum 150.48 mg, carboxymethylamylum natricum a corresp. natrium 0.756 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, kalii hydroxidum, e 172 (rubrum), pro capsula. - farmaco - synthetika

Temozolomid-Teva 250 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid-teva 250 mg capsule

teva pharma ag - temozolomidum - capsule - temozolomidum 250 mg, lactosum 209 mg, carboxymethylamylum natricum a corresp. natrium 1.05 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, e 172 (nigrum), pro capsula. - farmaco - synthetika

Carmustine medac (previously Carmustine Obvius) Unione Europea - italiano - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - carmustina - hodgkin disease; lymphoma, non-hodgkin - agenti antineoplastici - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Temozolomid Devatis 5 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid devatis 5 mg capsule

devatis ag - temozolomidum - capsule - temozolomidum 5 mg, lactosum 132.8 mg, carboxymethylamylum natricum a corresp. natrium max. 0.3 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, e 172 (flavum), e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - farmaco - synthetika

Temozolomid Devatis 20 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid devatis 20 mg capsule

devatis ag - temozolomidum - capsule - temozolomidum 20 mg, lactosum 182.2 mg, carboxymethylamylum natricum a corresp. natrium max. 0.5 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - farmaco - synthetika

Temozolomid Devatis 100 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid devatis 100 mg capsule

devatis ag - temozolomidum - capsule - temozolomidum 100 mg, lactosum 175.7 mg, carboxymethylamylum natricum a corresp. natrium max. 0.6 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - farmaco - synthetika

Temozolomid Devatis 140 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid devatis 140 mg capsule

devatis ag - temozolomidum - capsule - temozolomidum 140 mg, lactosum 246 mg, carboxymethylamylum natricum a corresp. natrium max. 0.9 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - farmaco - synthetika

Temozolomid Devatis 180 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid devatis 180 mg capsule

devatis ag - temozolomidum - capsule - temozolomidum 180 mg, lactosum 316.3 mg, carboxymethylamylum natricum a corresp. natrium max. 1.1 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - farmaco - synthetika

Temozolomid Devatis 250 mg Capsule Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

temozolomid devatis 250 mg capsule

devatis ag - temozolomidum - capsule - temozolomidum 250 mg, lactosum 154.3 mg, carboxymethylamylum natricum a corresp. natrium max. 0.9 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - farmaco - synthetika